Listen to article
6:30Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Published on 2 October 2026
Read article
I’ve spent more time than I’d care to admit in dreary waiting rooms, flicking through magazines from 2011 and wondering if the cure is worse than the ailment. The whole business of healthcare often feels archaic. It’s a world of paper prescriptions, appointments booked weeks in advance, and treatments that feel like a one size fits all solution. So, when someone tells me the next great medical breakthrough might be downloaded from an app store, my cynical eyebrow goes up. But then I look a bit closer, and I must admit, things are getting interesting.
We aren't talking about those wellness apps that tell you to drink more water or do a bit of mindfulness. This is an entirely new beast called digital therapeutics. Think of it as software that has gone through the same gruelling clinical trials as a new pill. It gets scrutinised and, if it passes, approved by regulators like the FDA. The result is a treatment for a specific condition, prescribed by a doctor, that just happens to live on your smartphone.
Now, a clever app is one thing, but a viable business is another. For years, great ideas in health tech have withered on the vine because nobody would pay for them. This is where the story changes. The real catalyst, to me, isn't the technology itself, it's the fact that insurance companies are starting to open their wallets.
Why? Because they’ve done the maths. An app that helps a patient manage their diabetes effectively might cost them a fraction of a single emergency room visit. It’s a simple calculation of risk and reward. This shift from a novelty to a reimbursable medical tool is what could transform digital therapeutics from a niche curiosity into a mainstream part of our healthcare system. When the people with the money see value, you know something significant is happening.
You can see this playing out across the market. You have companies like DarioHealth, which focuses squarely on managing chronic conditions like diabetes through its platform. Then there are players like GoodRx, which started in prescription discounts but is now branching into a broader digital health ecosystem. And of course, you have the telehealth giants like Teladoc, which are integrating these digital treatments into their virtual care services.
Each is taking a different path, but they are all betting on the same fundamental idea. That continuous, data driven care delivered through software can produce better outcomes, particularly for long term conditions that traditional medicine often struggles to manage day to day. It’s a fascinating landscape, and for those looking to understand the key players, thematic baskets like the Digital Therapeutics & Prescription Apps can offer a useful overview.
Of course, it would be foolish to think this is a straight road to success. The path is littered with potential pitfalls. Regulatory approval is a long and expensive slog, just as it is for any pharmaceutical company. Competition is also a real threat. What’s to stop a tech behemoth with deep pockets from deciding it wants a piece of the action and steamrolling the smaller pioneers?
Furthermore, many of these companies are still in their investment phase, burning through cash to fund research and development. Their success is not guaranteed, and the market can be incredibly sensitive to news about clinical trial results or regulatory hurdles. Investing here requires a stomach for potential volatility and an understanding that you’re backing an emerging industry, not a sure thing. The potential for growth is tied directly to these significant risks.
View the full Basket:Digital Therapeutics & Prescription Apps
View the full Basket:Digital Therapeutics & Prescription Apps
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 4 October 2026
Read article
Published on 4 October 2026
Read article
Published on 3 October 2026
Read article
Published on 3 October 2026
Read article
Published on 2 October 2026
Read article
